Free Trial
NASDAQ:LVTX

LAVA Therapeutics Q1 2024 Earnings Report

LAVA Therapeutics logo
$1.36 +0.01 (+0.73%)
Closing price 07/11/2025 03:56 PM Eastern
Extended Trading
$1.36 0.00 (-0.29%)
As of 07/11/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LAVA Therapeutics EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.23
One Year Ago EPS
N/A

LAVA Therapeutics Revenue Results

Actual Revenue
$6.99 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LAVA Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 21, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

LAVA Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 19, 2025, with a conference call scheduled on Wednesday, August 20, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

LAVA Therapeutics Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More LAVA Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LAVA Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LAVA Therapeutics and other key companies, straight to your email.

About LAVA Therapeutics

LAVA Therapeutics (NASDAQ:LVTX), Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation cancer immunotherapies. The company’s proprietary platform leverages the unique biology of gamma delta (γδ) T cells—immune cells that combine innate and adaptive functions—to create bispecific and multispecific antibodies designed to recruit and activate γδ T cells against a broad range of solid tumors and hematological malignancies.

At the core of LAVA’s pipeline is its Gammabody® platform, which engineers antibodies to precisely engage γδ T cell receptors in conjunction with tumor-associated antigens. Lead candidates include LAVA-051, a first-in-class bispecific targeting Vγ9Vδ2 T cells and CD1d for the treatment of hematological cancers, and LAVA-1207, which recruits Vγ9Vδ2 T cells to prostate-specific membrane antigen (PSMA) in prostate cancer. Additional preclinical programs aim to expand the technology to other solid tumor indications and novel tumor-specific targets.

Founded in 2016 and headquartered in Amsterdam with a research and clinical development presence in Boston, Massachusetts, LAVA has built a multidisciplinary team comprising immunologists, antibody engineers and clinical development experts. The company completed its initial public offering on the Nasdaq in 2021. Under the leadership of Chief Executive Officer J.P. Castaigne and Chief Scientific Officer Andreas Hofmann, LAVA continues to advance its portfolio through regulatory filings and early-stage clinical trials across Europe and North America.

View LAVA Therapeutics Profile

More Earnings Resources from MarketBeat